Group 1 - The company, GaoNeng Environment (603588.SH), is actively exploring resource recovery business in the rare earth sector, which is recognized as a significant strategic metal for the country [1]

Group 1 - The company Zhihu-W (02390.HK) announced a share buyback on February 11, spending $119,000 to repurchase 99,000 shares [1]

Core Viewpoint - The company, Haina Star Technology (08297.HK), announced that it will hold a board meeting on February 27, 2026, to review and approve the annual performance for the fiscal year ending March 31, 2025, and to consider the recommendation of a final dividend, if any. Trading of the company's shares remains suspended [1]. Group 1 - The board meeting is scheduled for February 27, 2026 [1] - The meeting will focus on reviewing and approving the annual performance for the year ending March 31, 2025 [1] - The company will consider whether to recommend a final dividend [1]

Core Viewpoint - The approval of a high-dose influenza virus split vaccine by Chengda Biological's subsidiary marks a significant step in addressing the growing demand for influenza prevention among the aging population in China [1][2] Group 1: Vaccine Approval and Characteristics - Chengda Biological's high-dose influenza virus split vaccine has received approval from the National Medical Products Administration to conduct clinical trials [1] - The vaccine is developed using WHO-recommended strains and has an antigen content four times that of standard-dose influenza vaccines, targeting individuals aged 60 and above [1] Group 2: Market Context and Implications - The aging population in China is increasing, leading to a heightened demand for effective influenza prevention strategies among the elderly [2] - Currently, there are no high-dose influenza vaccines approved for sale in China, making this clinical trial approval a crucial step for the company in responding to health aging strategies [2] Group 3: Future Development and Strategic Goals - Chengda Biological aims to continue its innovation-driven development strategy, enhancing its technological platform and the ability to translate research outcomes into products [2] - The company plans to advance the research and development of influenza vaccines and other key projects to improve public health and contribute to the high-quality development of China's biopharmaceutical industry [2]

格隆汇2月12日丨ST宁科(600165.SH)在投资者互动平台表示，公司暂无建设新的产品产线计划。 ...

为确保本行平稳运行，在关文杰先生的董事长任职资格获得监管机构核准之前，由霍学文先生代为履行 本行董事长、董事会战略与社会责任（ESG）委员会主任委员、董事会消费者权益保护委员会主任委员 及法定代表人职责，霍学文先生仍担任本行董事、董事会战略与社会责任（ESG）委员会委员、董事会 消费者权益保护委员会委员职务。 格隆汇2月12日丨北京银行(601169.SH)公布，公司董事会收到霍学文先生的辞职报告。因到龄离任，霍 学文先生申请辞去北京银行董事长、董事会战略与社会责任（ESG）委员会主任委员、董事会消费者权 益保护委员会主任委员职务。 ...

预期由2024财政年度之年度亏损及全面开支总额转为本年度之年度溢利及全面收入总额，主要归因于本 年度内，集团于其营运中实施严格的成本控制措施，从而提升营运效率，较2024财政年度录得更高的整 体利润率。 格隆汇2月12日丨濠江机电(01408.HK)公告，根据对集团截至2025年12月31日止年度(「本年度」)的未 经审计的综合财务报表的初步审查，以及董事会目前可获得的其他资料，预期集团将录得不多于澳门币 250万元的年度溢利及全面收入总额，而截至2024年12月31日止年度(「2024财政年度」)则录得约澳门 币250万元的年度亏损及全面开支总额。 ...

格隆汇2月12日丨法拉电子(600563.SH)在投资者互动平台表示，公司已参与特高压直流输电工程，相关 产品为换流阀的核心部件。该规划将对公司未来发展产生积极、长远的影响。公司将紧抓机遇，专注主 业，持续提升核心竞争力。公司投资的上海美星主营产品为电子变压器，产品主要应用于照明、通信等 领域。 ...

格隆汇2月12日丨金山软件(03888.HK)公告，2月12日耗资2000万港元回购72.1万股。 ...

格隆汇2月12日丨北森控股(09669.HK)公告，2月12日耗资81.6万港元回购14.3万股。 ...